<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01410162</url>
  </required_header>
  <id_info>
    <org_study_id>R-10-647</org_study_id>
    <secondary_id>17393</secondary_id>
    <nct_id>NCT01410162</nct_id>
  </id_info>
  <brief_title>Advagraf/Prograf Conversion Trial</brief_title>
  <acronym>SG#153</acronym>
  <official_title>A Randomized, Open Label, Cross Over Study to Examine the Impact of Prograf and Advagraf on Tacrolimus Exposure, Mycophenolic Acid Pharmacokinetics, Renal Allograft Function or Adverse Effects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norman Muirhead</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Canada, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Renal and kidney pancreas transplant patients will be randomized to once daily Advagraf or
      twice daily Prograf to assess changes in tacrolimus and mycophenolate mofetil exposure, renal
      allograft function, other relevant biochemical parameters and treatment related adverse
      effects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>renal function</measure>
    <time_frame>baseline to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bioequivalence of MPA exposure with Advagraf</measure>
    <time_frame>Baseline, 12 weeks and 24 weeks</time_frame>
    <description>Bioequivalence is measured using Pharmacokinetic monitoring of MPA plasma concentrations.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Renal Transplant</condition>
  <condition>Kidney Pancreas Transplant</condition>
  <arm_group>
    <arm_group_label>Advagraf</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prograf</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>tacrolimus extended release capsules vs Prograf</description>
    <arm_group_label>Advagraf</arm_group_label>
    <arm_group_label>Prograf</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal transplant or Renal Pancreas patients who are &gt; 12 months post transplant

          -  Stable allograft function defined as eGFR &gt; 30-60ml/min

          -  Renal patients who have a stable tacrolimus trough level of 5-8ng/ml in prior 3
             months; Renal pancreas patients who have a stable tacrolimus trough level of 3-10
             mg/ml in prior 3 months

          -  Receiving concomitant therapy with mycophenolate mofetil in a dose of 500-1000mg bid
             or equivalent

        Exclusion Criteria:

          -  Any surgical or medical condition, which in the opinion of the investigator, may place
             the patient at higher risk from his/her participation in the study, or is likely to
             prevent the patient from complying with the requirements of the study or completing
             the study.

          -  History of malignancy of any organ system, treated or untreated, within the past 5
             years whether or not there is evidence of local recurrence or metastases, with the
             exception of localized basal cell carcinoma of the skin.

          -  Treated rejection within 3 months of randomization.

          -  Increased serum creatinine &gt; 20% within 3 months of randomization.

          -  Subject is pregnant or breastfeeding

          -  Subject has significant co-morbid disease (eg. Malignancy or uncontrolled infection)
             or disability (e.g. cognitive deficit) which prevents understanding of, or adherence
             to, the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman Muirhead</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Health Sciences Centre Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2011</study_first_submitted>
  <study_first_submitted_qc>August 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2011</study_first_posted>
  <last_update_submitted>August 31, 2015</last_update_submitted>
  <last_update_submitted_qc>August 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Norman Muirhead</investigator_full_name>
    <investigator_title>Professor, Medicine University of Western Ontario</investigator_title>
  </responsible_party>
  <keyword>Renal</keyword>
  <keyword>Kidney/Pancreas</keyword>
  <keyword>Transplant</keyword>
  <keyword>conversion</keyword>
  <keyword>bioequivalence</keyword>
  <keyword>Mycophenolate Acid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

